On February 27, Gelonghui (002653.SZ) announced that Tibet Hisco Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as the “Company”), recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. HSK39775 tablets, intended for the treatment of advanced solid tumors.
Preclinical study results show that HSK39775 has shown potential efficacy in multiple tumor cell lines, and has strong anti-tumor activity in homologous recombinant repair defect models, and has potential to be used to treat cancer associated with loss of homologous recombination repair, especially cancer associated with BRCA mutations, such as breast cancer, ovarian cancer, and prostate cancer. Furthermore, HSK39775 has shown good selectivity and safety in preclinical studies, and is a small molecule drug with great potential for development. Currently, most of the world's same-target drugs are in the early stages of development. Among them, the highest stage of development is phase I clinical.